Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Anti-Obesity Prescription Drugs Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Anti-Obesity Prescription Drugs Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Orlistat
      • 1.3.3 Phentermine and Topiramate
      • 1.3.4 Bupropion and Naltrexone
      • 1.3.5 Lorcaserin
      • 1.3.6 Liraglutide
    • 1.4 Market Segment by Application
      • 1.4.1 Global Anti-Obesity Prescription Drugs Market Share by Application (2019-2025)
      • 1.4.2 Pediatric
      • 1.4.3 Adult
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Anti-Obesity Prescription Drugs Market Size
      • 2.1.1 Global Anti-Obesity Prescription Drugs Revenue 2014-2025
      • 2.1.2 Global Anti-Obesity Prescription Drugs Sales 2014-2025
    • 2.2 Anti-Obesity Prescription Drugs Growth Rate by Regions
      • 2.2.1 Global Anti-Obesity Prescription Drugs Sales by Regions 2014-2019
      • 2.2.2 Global Anti-Obesity Prescription Drugs Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Anti-Obesity Prescription Drugs Sales by Manufacturers
      • 3.1.1 Anti-Obesity Prescription Drugs Sales by Manufacturers 2014-2019
      • 3.1.2 Anti-Obesity Prescription Drugs Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Anti-Obesity Prescription Drugs Revenue by Manufacturers (2014-2019)
      • 3.2.2 Anti-Obesity Prescription Drugs Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Anti-Obesity Prescription Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.3 Anti-Obesity Prescription Drugs Price by Manufacturers
    • 3.4 Key Manufacturers Anti-Obesity Prescription Drugs Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Anti-Obesity Prescription Drugs Market
    • 3.6 Key Manufacturers Anti-Obesity Prescription Drugs Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 Orlistat Sales and Revenue (2014-2019)
      • 4.1.2 Phentermine and Topiramate Sales and Revenue (2014-2019)
      • 4.1.3 Bupropion and Naltrexone Sales and Revenue (2014-2019)
      • 4.1.4 Lorcaserin Sales and Revenue (2014-2019)
      • 4.1.5 Liraglutide Sales and Revenue (2014-2019)
    • 4.2 Global Anti-Obesity Prescription Drugs Sales Market Share by Type
    • 4.3 Global Anti-Obesity Prescription Drugs Revenue Market Share by Type
    • 4.4 Anti-Obesity Prescription Drugs Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Anti-Obesity Prescription Drugs Sales by Application

    6 United States

    • 6.1 United States Anti-Obesity Prescription Drugs Breakdown Data by Company
    • 6.2 United States Anti-Obesity Prescription Drugs Breakdown Data by Type
    • 6.3 United States Anti-Obesity Prescription Drugs Breakdown Data by Application

    7 European Union

    • 7.1 European Union Anti-Obesity Prescription Drugs Breakdown Data by Company
    • 7.2 European Union Anti-Obesity Prescription Drugs Breakdown Data by Type
    • 7.3 European Union Anti-Obesity Prescription Drugs Breakdown Data by Application

    8 China

    • 8.1 China Anti-Obesity Prescription Drugs Breakdown Data by Company
    • 8.2 China Anti-Obesity Prescription Drugs Breakdown Data by Type
    • 8.3 China Anti-Obesity Prescription Drugs Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Anti-Obesity Prescription Drugs Breakdown Data by Company
    • 9.2 Rest of World Anti-Obesity Prescription Drugs Breakdown Data by Type
    • 9.3 Rest of World Anti-Obesity Prescription Drugs Breakdown Data by Application
    • 9.4 Rest of World Anti-Obesity Prescription Drugs Breakdown Data by Countries
      • 9.4.1 Rest of World Anti-Obesity Prescription Drugs Sales by Countries
      • 9.4.2 Rest of World Anti-Obesity Prescription Drugs Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 F Hoffmann La Roche Ltd
      • 10.1.1 F Hoffmann La Roche Ltd Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Anti-Obesity Prescription Drugs
      • 10.1.4 Anti-Obesity Prescription Drugs Product Introduction
      • 10.1.5 F Hoffmann La Roche Ltd Recent Development
    • 10.2 Orexigen Therapeutics
      • 10.2.1 Orexigen Therapeutics Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Anti-Obesity Prescription Drugs
      • 10.2.4 Anti-Obesity Prescription Drugs Product Introduction
      • 10.2.5 Orexigen Therapeutics Recent Development
    • 10.3 Novo Nordisk A/s
      • 10.3.1 Novo Nordisk A/s Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Anti-Obesity Prescription Drugs
      • 10.3.4 Anti-Obesity Prescription Drugs Product Introduction
      • 10.3.5 Novo Nordisk A/s Recent Development
    • 10.4 Arena Pharmaceuticals
      • 10.4.1 Arena Pharmaceuticals Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Anti-Obesity Prescription Drugs
      • 10.4.4 Anti-Obesity Prescription Drugs Product Introduction
      • 10.4.5 Arena Pharmaceuticals Recent Development
    • 10.5 Glaxosmithkline
      • 10.5.1 Glaxosmithkline Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of Anti-Obesity Prescription Drugs
      • 10.5.4 Anti-Obesity Prescription Drugs Product Introduction
      • 10.5.5 Glaxosmithkline Recent Development
    • 10.6 Vivus
      • 10.6.1 Vivus Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of Anti-Obesity Prescription Drugs
      • 10.6.4 Anti-Obesity Prescription Drugs Product Introduction
      • 10.6.5 Vivus Recent Development
    • 10.7 Boehringer Ingelheim
      • 10.7.1 Boehringer Ingelheim Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of Anti-Obesity Prescription Drugs
      • 10.7.4 Anti-Obesity Prescription Drugs Product Introduction
      • 10.7.5 Boehringer Ingelheim Recent Development
    • 10.8 Alizyme
      • 10.8.1 Alizyme Company Details
      • 10.8.2 Company Description and Business Overview
      • 10.8.3 Sales, Revenue and Market Share of Anti-Obesity Prescription Drugs
      • 10.8.4 Anti-Obesity Prescription Drugs Product Introduction
      • 10.8.5 Alizyme Recent Development

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Anti-Obesity Prescription Drugs Sales Channels
      • 11.2.2 Anti-Obesity Prescription Drugs Distributors
    • 11.3 Anti-Obesity Prescription Drugs Customers

    12 Market Forecast

    • 12.1 Global Anti-Obesity Prescription Drugs Sales and Revenue Forecast 2019-2025
    • 12.2 Global Anti-Obesity Prescription Drugs Sales Forecast by Type
    • 12.3 Global Anti-Obesity Prescription Drugs Sales Forecast by Application
    • 12.4 Anti-Obesity Prescription Drugs Forecast by Regions
      • 12.4.1 Global Anti-Obesity Prescription Drugs Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Anti-Obesity Prescription Drugs Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      Growing demand for obesity is one of the recent trends in the global Anti-Obesity Prescription Drugs market. Moreover, this trend is further anticipated to drive the global Anti-Obesity Prescription Drugs market over the forecast period. Furthermore, growing obesity due unhealthy food and lifestyle such as intake of drugs due to stress, alcohol leads to growing demand for obesity management resulting in growth of this trend.
      In 2019, the market size of Anti-Obesity Prescription Drugs is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of 5.0% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Anti-Obesity Prescription Drugs.

      This report studies the global market size of Anti-Obesity Prescription Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Anti-Obesity Prescription Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      F Hoffmann La Roche Ltd
      Orexigen Therapeutics
      Novo Nordisk A/s
      Arena Pharmaceuticals
      Glaxosmithkline
      Vivus
      Boehringer Ingelheim
      Alizyme

      Market Segment by Product Type
      Orlistat
      Phentermine and Topiramate
      Bupropion and Naltrexone
      Lorcaserin
      Liraglutide

      Market Segment by Application
      Pediatric
      Adult

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Anti-Obesity Prescription Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Anti-Obesity Prescription Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Anti-Obesity Prescription Drugs are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now